<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942025000200210</article-id>
<article-id pub-id-type="doi">10.30827/ars.v66i2.31894</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Identificación y caracterización de eventos adversos asociados a la utilización de Cannabis: Revisión estructurada]]></article-title>
<article-title xml:lang="en"><![CDATA[Identification and characterization of adverse events associated with Cannabis use: A comprehensive review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva Rivera]]></surname>
<given-names><![CDATA[Valeria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lopera]]></surname>
<given-names><![CDATA[Valentina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia Grupo de Investigación Promoción y Prevención Farmacéutica ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Granada Grupo de Investigación en Atención Farmacéutica ]]></institution>
<addr-line><![CDATA[Granada ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<volume>66</volume>
<numero>2</numero>
<fpage>210</fpage>
<lpage>224</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942025000200210&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942025000200210&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942025000200210&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  La disponibilidad de información estructurada de eventos adversos asociados al cannabis puede contribuir a la utilización adecuada del cannabis medicinal.  Objetivo:  Sintetizar y caracterizar los eventos adversos asociados a la utilización de cannabis.  Método:  Revisión estructurada de eventos adversos asociados a la utilización del cannabis en PubMed, utilizando términos Mesh (&#8220;Cannabis&#8221; And (&#8220;Drug-Related Side Effects or Adverse Reactions&#8221;), en humanos, publicados en inglés o español y acceso a texto completo, hasta noviembre 1 de 2024. Dos investigadores revisaron los artículos identificados y definieron su inclusión. Adicionalmente, se incluyeron referencias de artículos consideradas de interés.  Resultados:  Se identificaron 47 eventos adversos asociados al uso de cannabis, afectando principalmente el sistema nervioso central y cardiovascular, en especial desórdenes mentales, somnolencia y afecciones gastrointestinales. No se identificaron eventos adversos mortales relacionados al uso de cannabis.  Conclusiones:  La utilización de cannabis se asocia con la presentación de eventos adversos, en especial en los sistemas nervioso central y cardiovascular. Es necesario más estudios orientados a identificar y caracterizar eventos adversos asociados al cannabis.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Available structured information about adverse events related to cannabis can contribute to appropriate use medical cannabis.  Objective:  Summarize and characterize the adverse events related to cannabis use.  Method:  Comprehensive review regarding to adverse events associated to cannabis use in PubMed. Mesh terms (&#8220;Cannabis&#8221; and &#8220;Drug-Related Side Effects and Adverse Reactions&#8221;) were employed, focusing on human studies published in English or Spanish with full-text access, up to November 1, 2024. Two researchers reviewed the identified articles and reached a consensus on their inclusion. Additionally, relevant references from these articles were considered.  Results:  A total of 47 adverse events associated to cannabis use were identified, mainly affecting the central nervous and cardiovascular systems, especially mental disorders, somnolence, and gastrointestinal conditions. No fatal adverse events were identified related to cannabis.  Conclusions:  The use of cannabis is associated to adverse events, particularly in the central nervous and cardiovascular systems. More studies are needed to identify and characterize adverse events associated to cannabis.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cannabis medicinal]]></kwd>
<kwd lng="es"><![CDATA[cannabis recreacional]]></kwd>
<kwd lng="es"><![CDATA[cannabinoides]]></kwd>
<kwd lng="es"><![CDATA[eventos adversos]]></kwd>
<kwd lng="es"><![CDATA[revisión estructurada]]></kwd>
<kwd lng="en"><![CDATA[Medical cannabis]]></kwd>
<kwd lng="en"><![CDATA[recreational cannabis]]></kwd>
<kwd lng="en"><![CDATA[cannabinoids]]></kwd>
<kwd lng="en"><![CDATA[adverse drug events]]></kwd>
<kwd lng="en"><![CDATA[comprehensive review]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skypala]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jeimy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brucker]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabis-related allergies: An international overview and consensus recommendations]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2022</year>
<volume>77</volume>
<page-range>2038-52</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[McCartney]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Suraev]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence]]></article-title>
<source><![CDATA[Clinical and Translational Science]]></source>
<year>2023</year>
<volume>16</volume>
<page-range>10-30</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marques Azzini]]></surname>
<given-names><![CDATA[GO]]></given-names>
</name>
<name>
<surname><![CDATA[Marques Azzini]]></surname>
<given-names><![CDATA[VO]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol for musculoskeletal regenerative medicine]]></article-title>
<source><![CDATA[Experimental Biology and Medicine]]></source>
<year>2023</year>
<volume>248</volume>
<page-range>445-55</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gottschling]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ayonrinde]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Bhaskar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety considerations in cannabinoid-based medicine]]></article-title>
<source><![CDATA[International Journal of General Medicine]]></source>
<year>2020</year>
<volume>13</volume>
<page-range>1317-33</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[DiNitto]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Marti]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sex differences in cannabis forms and exposure reasons in cannabis-related poison control center cases aged 50]]></article-title>
<source><![CDATA[Clinical Toxicology]]></source>
<year>2021</year>
<volume>59</volume>
<page-range>822-31</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Subramaniam]]></surname>
<given-names><![CDATA[VN]]></given-names>
</name>
<name>
<surname><![CDATA[Menezes]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[DeSchutter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The cardiovascular effects of marijuana: Are the potential adverse effects worth the high?]]></article-title>
<source><![CDATA[Missouri Medicine]]></source>
<year>2019</year>
<volume>116</volume>
<page-range>146-53</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A primer on medicinal cannabis safety and potential adverse effects]]></article-title>
<source><![CDATA[Australian Journal of General Practice]]></source>
<year>2021</year>
<volume>50</volume>
<page-range>345-50</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lombardi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gunter]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tanner]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ohio physician attitudes toward medical cannabis and Ohio&#8217;s medical marijuana program]]></article-title>
<source><![CDATA[Journal of Cannabis Research]]></source>
<year>2020</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[McKenzie]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Bossuyt]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Boutron]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Mulrow]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The PRISMA 2020 statement: an updated guideline for reporting systematic reviews]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bar-Sela]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zalman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Semenysty]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of dosage-controlled cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients: Pilot study]]></article-title>
<source><![CDATA[Integrative Cancer Therapies]]></source>
<year>2019</year>
<volume>18</volume>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crescioli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lombardi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bettiol]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database]]></article-title>
<source><![CDATA[British Journal of Clinical Pharmacology]]></source>
<year>2020</year>
<volume>86</volume>
<page-range>106-20</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raghunathan]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brens]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vemuri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In the weeds: a retrospective study of patient interest in and experience with cannabis at a cancer center]]></article-title>
<source><![CDATA[Supportive Care in Cancer]]></source>
<year>2022</year>
<volume>30</volume>
<page-range>7491-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Richards]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms for the risk of acute coronary syndrome and arrhythmia associated with phytogenic and synthetic cannabinoid use]]></article-title>
<source><![CDATA[Journal of Cardiovascular Pharmacology and Therapeutics]]></source>
<year>2020</year>
<volume>25</volume>
<page-range>508-22</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rickner]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kleinschmidt]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A little &#8216;dab&#8217; will do ya&#8217; in: a case report of neuro- and cardiotoxicity following use of cannabis concentrates]]></article-title>
<source><![CDATA[Clinical Toxicology]]></source>
<year>2017</year>
<volume>55</volume>
<page-range>1011-3</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boukerche]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Khalil]]></surname>
<given-names><![CDATA[MZ]]></given-names>
</name>
<name>
<surname><![CDATA[Shirk]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serotonin syndrome misdiagnosed in a patient who used a cannabis dab pen]]></article-title>
<source><![CDATA[Primary Care Companion for CNS Disorders]]></source>
<year>2022</year>
<volume>24</volume>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mangot]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bad trip due to anticholinergic effect of cannabis]]></article-title>
<source><![CDATA[General Hospital Psychiatry]]></source>
<year>2013</year>
<volume>35</volume>
<page-range>682.e5-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bao]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neonate death due to marijuana toxicity to the liver and adrenals]]></article-title>
<source><![CDATA[American Journal of Case Reports]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>1874-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liskow]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Liss]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Allergy to marihuana]]></article-title>
<source><![CDATA[Annals of Internal Medicine]]></source>
<year>1971</year>
<volume>75</volume>
<page-range>571-3</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corso]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bacle]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Demay]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Place of therapeutic cannabis in France and safety data: A literature review]]></article-title>
<source><![CDATA[Annales Pharmaceutiques Françaises]]></source>
<year>2023</year>
<volume>81</volume>
<page-range>583-95</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabis pen-induced psychosis in a first-time adolescent user]]></article-title>
<source><![CDATA[Psychopharmacology Bulletin]]></source>
<year>2023</year>
<volume>53</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>61-5</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nadeem]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serotonin syndrome and cannabis: A case report]]></article-title>
<source><![CDATA[Australasian Psychiatry]]></source>
<year>2024</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>100-1</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krebs]]></surname>
<given-names><![CDATA[M-O]]></given-names>
</name>
<name>
<surname><![CDATA[Kebir]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Jay]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders]]></article-title>
<source><![CDATA[European Journal of Pain]]></source>
<year>2019</year>
<volume>23</volume>
<page-range>1225-33</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andréasson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Allebeck]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Engström]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabis and schizophrenia. A longitudinal study of Swedish conscripts]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>1987</year>
<volume>2</volume>
<page-range>1483-6</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arendt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Foldager]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabis-induced psychosis, and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases]]></article-title>
<source><![CDATA[The British Journal of Psychiatry]]></source>
<year>2005</year>
<volume>187</volume>
<page-range>510-5</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldberger]]></surname>
<given-names><![CDATA[CZ]]></given-names>
</name>
<name>
<surname><![CDATA[Dervaux]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gourion]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variable individual sensitivity to cannabis in patients with schizophrenia]]></article-title>
<source><![CDATA[International Journal of Neuropsychopharmacology]]></source>
<year>2010</year>
<volume>13</volume>
<page-range>1145-54</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sultan]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Millar]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Sullivan]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review and meta-analysis of the in vivo haemodynamic effects of &#916;8-tetrahydrocannabinol]]></article-title>
<source><![CDATA[Pharmaceuticals]]></source>
<year>2018</year>
<volume>11</volume>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beaumont]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carlsson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans]]></article-title>
<source><![CDATA[British Journal of Pharmacology]]></source>
<year>2009</year>
<volume>156</volume>
<page-range>153-62</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thiele]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Marsh]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[French]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2018</year>
<volume>391</volume>
<page-range>1085-96</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wade]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Makela]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[House]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis]]></article-title>
<source><![CDATA[Multiple Sclerosis]]></source>
<year>2006</year>
<volume>12</volume>
<page-range>639-45</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lorenzetti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Solowij]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yücel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of cannabinoids in neuroanatomic alterations in cannabis users]]></article-title>
<source><![CDATA[Biological Psychiatry]]></source>
<year>2016</year>
<volume>79</volume>
<page-range>e17-31</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gruber]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Sagar]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Marijuana on the mind? The impact of marijuana on cognition, brain structure, and brain function, and related public policy implications]]></article-title>
<source><![CDATA[Policy Insights from the Behavioral and Brain Sciences]]></source>
<year>2017</year>
<volume>4</volume>
<page-range>104-11</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karniol]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Carlini]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative studies in man and in laboratory animals on 8- and 9-trans-tetrahydrocannabinol]]></article-title>
<source><![CDATA[Pharmacology]]></source>
<year>1973</year>
<volume>9</volume>
<page-range>115-26</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karniol]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Shirakawa]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of delta9-tetrahydrocannabinol and cannabinol in man]]></article-title>
<source><![CDATA[Pharmacology]]></source>
<year>1975</year>
<volume>13</volume>
<page-range>502-12</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zimmer]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Bickel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dittrich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes of simple somatic parameters by delta-9-trans-tetrahydrocannabinol (delta-9-THC) in a double-blind study]]></article-title>
<source><![CDATA[Arzneimittelforschung]]></source>
<year>1976</year>
<volume>26</volume>
<page-range>1614-6</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haney]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Opioid antagonism of cannabinoid effects: Differences between marijuana smokers and non-marijuana smokers]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2007</year>
<volume>32</volume>
<page-range>1391-403</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klooker]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
<name>
<surname><![CDATA[Leliefeld]]></surname>
<given-names><![CDATA[KEM]]></given-names>
</name>
<name>
<surname><![CDATA[Van Den Wijngaard]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients]]></article-title>
<source><![CDATA[Neurogastroenterology and Motility]]></source>
<year>2011</year>
<volume>23</volume>
<page-range>30-5</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gracie]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hancox]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabis use disorder and the lungs]]></article-title>
<source><![CDATA[Addiction]]></source>
<year>2021</year>
<volume>116</volume>
<page-range>182-90</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lorenz]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Uno]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wolinsky]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of marijuana smoking on pulmonary disease in HIV-infected and uninfected men: A longitudinal cohort study]]></article-title>
<source><![CDATA[EClinical Medicine]]></source>
<year>2019</year>
<volume>7</volume>
<page-range>55-64</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Owen]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Sutter]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Albertson]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Marijuana: Respiratory tract effects]]></article-title>
<source><![CDATA[Clinical Reviews in Allergy &amp; Immunology]]></source>
<year>2014</year>
<volume>46</volume>
<page-range>65-81</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aviram]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Samuelly-Leichtag]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of cannabis-based medicines for pain management: A systematic review and meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Pain Physician]]></source>
<year>2017</year>
<volume>20</volume>
<page-range>E755-96</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monte]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Shelton]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute illness associated with cannabis use, by route of exposure: An observational study]]></article-title>
<source><![CDATA[Annals of Internal Medicine]]></source>
<year>2019</year>
<volume>170</volume>
<page-range>531-7</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<collab>WHO Collaborating Centre for International Drug Monitoring</collab>
<source><![CDATA[The importance of pharmacovigilance]]></source>
<year>2002</year>
<publisher-loc><![CDATA[Geneve ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopera]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical relevance of drug interactions with cannabis: A systematic review]]></article-title>
<source><![CDATA[Journal of Clinical Medicine]]></source>
<year>2022</year>
<volume>11</volume>
</nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yadav]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current cannabidiol safety: A review]]></article-title>
<source><![CDATA[Current Drug Safety]]></source>
<year>2023</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>465-73</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="">
<collab>United Nations Department of Economic and Social Affairs, Population Division</collab>
<source><![CDATA[World Population Prospects]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Perel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mensah]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Ezzati]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension]]></article-title>
<source><![CDATA[Nature Reviews Cardiology]]></source>
<year>2021</year>
<volume>18</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>785-802</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solmi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Toffol]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2023</year>
<volume>382</volume>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheikh]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Dua]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoids]]></article-title>
<source><![CDATA[StatPearls]]></source>
<year>2024</year>
<publisher-loc><![CDATA[Treasure Island (FL) ]]></publisher-loc>
<publisher-name><![CDATA[StatPearls Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Langnas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Maze]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Use of Adrenergic Receptor Ligands in Acute Care Settings]]></article-title>
<source><![CDATA[Handbook of Experimental Pharmacology]]></source>
<year>2024</year>
<volume>285</volume>
<page-range>617-37</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levinsohn]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical uses of cannabis and cannabinoids in the United States]]></article-title>
<source><![CDATA[Journal of the Neurological Sciences]]></source>
<year>2020</year>
<volume>411</volume>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
